BioCryst names David Jenkins chief scientific officer

• BioCryst appointed David W. Jenkins as chief scientific officer, effective immediately, in a newly created role.
• Jenkins reports to Chief Research and Development Officer Sandeep Menon.
• He will build and lead a research team focused on external innovation partnerships to accelerate rare disease therapy development.
• Jenkins previously served as senior vice president, head of research and external innovation at Ipsen.
• Earlier roles included scientific leadership posts at TESARO, MedImmune, Novartis, AstraZeneca.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCryst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607150700PRIMZONEFULLFEED9762228) on July 15, 2026, and is solely responsible for the information contained therein.